CHARLOTTESVILLE, Va.--(BUSINESS WIRE)--Cavion, Inc., a clinical stage biopharmaceutical company, announced today that Dr. Spyridon "Spyros" Papapetropoulos has joined as Executive Vice President, Research and Development and Chief Medical Officer. Dr. Papapetropoulos will lead Cavion’s research and development organization to advance therapies based on the company’s T-type calcium channel (Cav3) platform.
- Published: Wednesday, 09 August 2017 13:59
We are pleased to announce overwhelming investor support for another successful financing completed this month. Several early stage venture funds participated in the financing, in addition to high net worth, successful business leaders from across the U.S.
Our Story and the Financing
Mission Secure's largest financing to date will further our journey to protect control systems from cyber attacks in defense, oil & gas, power and transportation. The original concepts began in 2010 borne out of requests from the U.S. Department of Defense to identify cyber attacks on weapons systems and weapons platforms and still be able to carry out the mission - cyber resiliency. The University of Virginia began researching the topic leading to early prototypes for autonomous vehicles and various military applications. Successful entrepreneurs with proven track records taking novel technology and commercializing it for homeland security, public safety and clean energy co-founded Mission Secure in the summer of 2014 with the original UVA research team.
Full story can be found at Charlottesville Tomorrow here